Jazz Pharmaceuticals (JAZZ) 10 Nov 222022 Q3 Earnings call transcript

Company Profile

Participants

Andrea Flynn	VP and Head, IR
Bruce Cozadd	Chairman and CEO
Dan Swisher	President
Rob Iannone	EVP, Global Head of R&D
Renée Galá	EVP and CFO
Kim Sablich	EVP and General Manager, North America
Ken Cacciatore	Cowen
Jessica Fye	JPMorgan
Jason Gerberry	Bank of America
David Amsellem	Piper Sandler
Marc Goodman	SVB
Ami Fadia	Needham
Ash Verma	UBS
Madhu Kumar	Goldman Sachs
Gary Nachman	BMO Capital Markets
Annabel Samimy	Stifel
Gregory Renza	RBC Capital

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today, Andrea Flynn, Vice President, Vice President of Investor Relations. ahead. go Please

Andrea Flynn

of and today, its operator presentation everyone. Jazz our release Investors Today, this refer may Thank the website. is to quarter good also XXXX reported press section the on third is issued slide website. financial Pharmaceuticals Investors webcast also earlier you, we available afternoon, our which results. accompanying to The posted

today’s our contained or differ We webcast SEC closing in Officer; agreement actual those Executive statements and events, with future as related forward-looking Dan potential duty programs call Vision the in obligation We our statements Global XXXX, are performance, Sablich, factors milestones, may President release, to Executive timing, company’s those includes that in and regulatory forward-looking Bruce our from Q&A. Officer; subject involve and Chief and Renée two, financial the statements. General our from XXXX results events, and review made forward-looking contained no to to and for today Zanidatamab activities and slide statements development press expected and encourage to undertake and On expectations contained uncertainties slide certain President deck, Iannone, these Galá, statements performance, Vice statements. US, to which the Executive licensing in respect to is Operating that results On and to those Chief today’s Head I’ll Chief will team related cause that our Chairman, Financial growth Swisher, and and disclosure results, and update Rob could anticipated Kim Officer; join Vice that actual on Executive remind including operating the Cozadd, you guidance document, for condition, President to identify goals risks pipeline, Manager, our forward-looking such of and for latest today’s webcast. which in R&D. cause and commercialization and President, the differ materially you materially Vice

we’ll in the slide measures. GAAP included Investors release this non-GAAP discuss and today’s are to over to website. three, presentation of call press financial section Bruce. non-GAAP Turning available on measures to I’ll in on turn Reconciliations our slide of now the the webcast, financial

Bruce Cozadd

quarter, the on three the based raising performance these and midpoints in of bottom-line significant all Good and across joining for Andrea. on slide our growth us year. quarters revenue call. midpoint you, and to on through Thank start neurology first XXXX, guidance, we enables thanks third today. guidance the year reflecting year-over-year afternoon, that our report of our top strong and for increases productive quarter, deliver I'm of to projections. both other of performance areas of later the everyone, five. In us the are in building net pleased I'll oncology the business operational discuss sales full the half will our a our guidance to first Renée updates

Xywav adoption XXXX, Our have to to we're in continues another seeing commercial more are taking we narcolepsy milestone. achieved both In Xyrem. franchise, well. important idiopathic than and are pleased or compelling of business Exiting execute IH, hypersomnia, patients neuroscience narcolepsy now October our and Xywav there

our durability the Xywav of commercial component a we ahead, Looking remain of portfolio. as core confident in

and to for for by key are Epidiolex's in paving commercial recently, the of the driven confident underlying remain we cornerstone achieve market. We become a way in in this seeing status. refractory we and growth Epidiolex, For believe completed potential process launch reimbursement pricing And European treatment Epidiolex France, seizures blockbuster demand. can

lung cell established oncology. is choice of Zepzelca cancer. as in small treatment second-line to the Moving

within Rylaze that strong expanding prescribers to detailed Our remains address focused later ongoing as therapy. of the continued. available quarter, the clinical coli-derived the had patient therapy well has from who momentum will the only reaction indication development as benefit Rylaze E. in looking additional a another may to to as on across with a populations overview are provide Dan our asparaginase. performance experience patients commercial US in who portfolio call. hypersensitivity efforts

tumors in And Our acquire pan-RAF starts. as Phase mutations our as JZPXXX, a in that pipeline Japan our or novel the part inhibitor the well MAPK to clinical in of quarter, efforts trial will seizures, evaluating agreement comments markets. for including with of patient enrolled EMAS, provide were the productive multiple our month, trial in trial again Rob pivotal our We the for this evaluating X a patients We enrolled in the and later treatment initiated US, rights first solid contain call. Parkinson's zanidatamab, and myoclonic Phase Epidiolex, trial disease which epilepsy in licensing our Europe, the ongoing essential first on announced trial with pipeline antibody last we Japan. in a tremor. to programs for initiated agreement expand we suvecaltamide in our development patient in commercialization And Zymeworks with pathway. other in HERX-targeted Xb bispecific Phase atonic additional our just late-stage tremor, as further progress, X to pipeline our Phase zanidatamab X with complements Epidiolex trial

and corporate three company; pipeline commercial, revenue with includes grow XXXX driving combination potential from therapies billion Vision positioned we're value of enhanced and and a components existing in emerging excellence. transform pipeline to six. commercial, our growth Starting to $X development. sustainable central to we through slide products, as XXXX operational to our new Turning

road ending and addressing pipeline of R&D of novel and by of approvals transaction percentage a an advancing to operating and development we We adjusted quarter across neuroscience appropriate anticipate entering model business and ensure as product was points of place after our structure order example to quarter excellence, needs XXXX map, plan we'll I'll in more the will have patient With we initiative the progress to to the our that accomplishments delivering call XXXX both the could update call the line corporate XXXX development. XXXX. for contribute Rob turn top financial at from programs, corporate in to The continuing our our Vision line. and to position bottom is with is to delivering review in a commercial the Dan? Dan in And XX% goals. share considerable business oncology we operating to XXXX, scale, an a then through the X corporate the which objectives. the and pipeline our end well margin our will key year, five invest programs continue combination our in meet transform R&D while least we our significant a for to our zanidatamab commercial business us Vision provide momentum to and achieve through by Our that up decade performance, strong to the organization to and programs. existing development over to of on third now including open operational believe on XXXX improve Q&A. our positioned third overview, update, Renée

Dan Swisher

performance. pleased the progress we've slide commercial on to about Starting quarter eight. excited made strong with and I'm third Bruce. report portfolio neuroscience the on our Thanks, on

approximately active increased product. meaningfully maintaining patient advanced approximately we patients In lower are our and IH. oxybate quarter, oxybate strong X,XXX last average both the XX,XXX and to year. third the momentum care narcolepsy in We representing growth quarter franchise. exiting There from sodium same with approximately Xywav compared the XX% adoption of were patients period oxybate for active resulting positive With have to a Xywav,

strong see X,XXX patients the quarter Xywav uptake to of and we Xywav. narcolepsy in exited narcolepsy third quarter continue We with for the approximately taking

Xywav Xyrem. reached narcolepsy patients an with taking mentioned, Bruce and milestone As we've more important

to addition the patients, narcolepsy Xywav. new Xywav Xyrem are prescribed of of continued adoption In patients majority being large to current oxybate among

educational our expect high IH growth the a are sodium to receptivity continued that of of and strong substantial with IH, market the a in and benefits for lower therapy. trend There we resonating oxybate We have in level With new opportunity. a efforts around is continue engagement patients. prescribers adoption as

narcolepsy par to the importantly, on reimbursement we and secured have prescriber IH – We with base. grow continue

and in prescribers for practices, IH the As educating own the physicians identifying taking therapy. and within on increased for is initiating enthusiasm potential about IH this and benefits observe X,XXX market. Xywav clinical confident there were for to diagnosis its underserved its patient and ability and our IH the third seeing prescribing they we're therapy identification. quarter, in Xywav Exiting are IH their gain are FDA-approved patients in have to focused we patients appropriate experience Xywav, opportunity and maximize only we first approximately

the both market competition only authorized and the the oxybate of choice potentially IH. only narcolepsy that available. XXXX, sodium Xywav becomes approved is Xywav enter for be and expect generics oxybate even and branded oxybate as the is We will lower as in

have Xywav continue is contribute meaningfully We that confidence Jazz's to will durable that a to commercial product portfolio.

slide to compared In demand. nine. the by period of sales the Epidiolex, net increased XXXX, XX% primarily to by product quarter year, in last third driven Turning same

is market placebo. their growth limited taken also US care positive a is have also nearly that strong refractory treatment with the Epidiolex, healthcare in data in XX% reducing highlight of reimbursement of been as Clobazam seizures begin of We're professionals brand are Clobazam development combination, for providers has with and in LGS the is treatment anti-epilepsy TSC., XX% nearly compared XX% whole. grow, pleased Both for frequency and in reduce on data XX% approximately to in we a plus synergistic health volume are of the data. we given in combination patients Epidiolex, with TSC for widely Clobazam outside with therapies, used Epidiolex impressed an in indicates LGS, experience markets patient's and is Polypharmacy healthcare in overall Epidiolex epilepsy to prescribers the of have to moving anti-seizure regimens. treatment resonating seizure into demonstrated treatment effects approach strategy using a the relevant pricing is incorporating the have one process Our rationale US engagement adoption very Clobazam. in frequency healthcare with to to by professionals plus and up research In shown completed There and combination These our the dominant and have continues been France. providers Clobazam Epidiolex who been most market algorithm. the one and and that and Dravet around the reduction continued have the Dravet promotionally which Epidiolex and in offering nature of giving Epidiolex particularly effectiveness seizure recently sensitive Epidiolex

launch European markets, major Spain reimbursed be Germany, point and at to this United expect which in and five including later Epidiolex all Kingdom, available will We France, year, Italy. commercially the

markets new multiple also additional opportunity from We indication this have for launches next. throughout and and coming growth year

Given and a will with other standard in anti-epilepsy and Epidiolex' confident ability market the be emerge to its therapies, global treatment-resistant range of we as care drug of differentiation wide it combined epilepsies. a remain

Now moving I'll with to on oncology. Zepzelca Slide XX. begin

cancer. the were sales We product net have as choice established in line expectations. small treatment in In Zepzelca third quarter, second-line our cell of lung with

in a accrual reduction in Zepzelca's As impacted XXXX our product we due returns. actual favorably XXXX third was million, by earnings approximately the were returns XQ which announcement, to quarter sales rate, $XX to noted lower-than-estimated net relating

lung believe observational Excluding compared also by will around trials current depth, share same in types, studies first-line investing Zepzelca's market new ways plans increased indication exploring in generate cover by period we tumor patients. for range other utility in We're XXXX. expand that impact, future and which our our patient Zepzelca sales the broad small XQ providing further and populations. approximately that growth to cell product net additional the second-line cancer a to data cell in development more real-world XX% in also small will evidence opportunity of XXXX meaningful for in in cancer includes lung Rob in

XX. to Slide Turning

therapy high-quality a We see and of reaction E. for third in have demand and have our awareness in of the to customers continued available launch prescribers, asparaginase. Rylaze US a Rylaze's hypersensitivity supply reliable position US, who XXXX. only brand to quarter the the patients confidence among strong as coli-derived product This in since robust reflects to

best We treatment initial professionals been universally has almost asparaginase encouraged healthcare continue use switching that of to to and that has non-E. availability there hypersensitivity practice coli-derived in pediatric of been clinical returning the increasing to when and hear Rylaze adults. protocols are there on we based earlier the Rylaze, from Rylaze and an of are observed. young see is to oncology in US reaction adolescents adopted they

provide Now I the Rob? to will R&D update. over Rob turn call to an

Rob Iannone

agreement our HERX-targeted trial or by this in to BTC such enable data in XXXX. approval GEA. as as expected in GEA are year-end, to the This things biliary on we in larger biparatopic mid-October, kick adenocarcinoma, In tract professionals rights an I'll therapy and to us quickly XX. novel extremely other approval Thanks allow to program. Dan. care drug Zanidatamab. is cancer license real-world a well X promising deliver potential the includes development support antibody experience Potential bispecific to current as ongoing to that possible. Zanidatamab patients BTC performance announced commercialization to gain slide pivotal pivotal from with populations has off and is transform The Topline BTC, in data multiple a prior the clinical with gastroesophageal potential trial expected HERX-expressing health that ongoing designed would in this that is for could binding in Phase and data near-term from standard-of-care readouts Zanidatamab registration. program cancers. are cancer anticipated topline

As HERX-expressing monotherapy see activity overview therapies. to potential of the team GEA. near-term beyond with with cases multiple an including at inform to shared Xymarks that [ph], patients. Slide will realizing trials provide BTC, our full the forward tumor opportunities. looking across prior ongoing And objective achieve expected I'm Zanidatamab development oncologist, to to of data XX We're R&D HERX impressed types, the our resistant Zanidatamab to an working experienced provides of are

LGS trial pipeline. advancing across TSC programs that are Phase that with Japan a in October. neuroscience, report of patient for we We initiated includes the enrolled Epidiolex Dravet, to pleased and first our I'm pivotal in number X have the Within

label trial We or for with atonic provide first the X in type. our have Phase and add initiated seizures, Epidiolex data also myoclonic This a potential would our indication a epilepsy clinical floor EMAS. fourth on seizure to

the separate a our trial the by in for Our year. patient of of for patient is to And in Suvecaltamide completed essential disorder for Phase too, we analysis the treatment JZPXXX disease, have Suvecaltamide, expect progressing, and and stress initiated of Xb nabiximols trial. significant or Parkinson's based end first MSSX post-traumatic on need, Phase X enroll trial the We've trial the our as Phase for X evidence tremor. is JZPXXX, preclinical

regulatory We pipeline as approval assessed sclerosis as have nabiximols program's the US the our to broader support opportunities. multiple potential well of for the in in to spasticity related context

and the currently complete impact colleagues and clinical who sites, clinical discontinue There will the in the spasticity the the extend of X On name enrolled of is controlled trial in study outside to based comprehensive approved three brand for was We clinical our in the the have to made recent decision trial including the program. profile. per clinical no at want US to patients, behalf families Phase gratitude MS-related patients trial, nabiximols, treatment the a Europe. randomized for investigators, they to Sativex, my their Jazz, participated nabiximols trials positive the completed program, trials. on I

continuing outside patients with the from benefit to confers Sativex that of so therapy. of remains availability markets MS-related it believe is that to where the to Sativex specificity the approved, it available who in to patients XX benefit continue support We US and are

about We patient are also remain address cannabinoid those Epidiolex, the GW with needs. to platform the including committed cannabinoid excited advancing unmet beyond potential programs, critical to and

Moving to oncology.

in cancer. lung trial observational own cell second-line run in cancer and Zepzelca. Phase in post-marketing second-line our ongoing small X extensive-stage effort cell We Roche first-line with X trial PharmaMar, confirmatory for by supported combination Jazz execute cell continue A being cancer. robust to our This and Zepzelca partner, lung evaluate by includes an development in small to lung small Phase our trial Tecentriq

basket a Phase X in We Zepzelca are other solid tumors also in trial. exploring

label weekend Friday Currently, Turning sBLA dosing, at asparaginase on Wednesday XX hours Rylaze, XX This review milligrams continuing on of clinical squared current is meter clinically a Monday, update milligrams every treatment. for entire to practice serum is schedule per squared. receiving to Rylaze maintain patients dosing dosing allow in our our to the the FDA to to line with labeled to Monday which Wednesday, duration activity intramuscular level Friday. XX through per patients milligrams and special, XX meaningful and with more squared avoid schedule, is meter a would meter per of

We dosing review to administration. BLA, support intravenous a program. Friday, reviewed also our real-time to IV Monday, schedule the under Similar and both supplemental the completed formulation original sBLA separate Wednesday, of the review the being are BLAs oncology

the have While they these Rylaze improve a usage, on we significant the do not label to do experience patients. updates clinicians have would for believe and potential impact

Friday, as We dosing administration submission Wednesday, Agency have XX-hour well potential Medicines also XXXX. every MAA European which an with and for schedules, Monday, and Rylaze, to IM in the approval included completed IV as

at our October. that contain of Phase earlier patient mutations milestone the reached stage pan-RAF solid the MAP JZPXXX, inhibitor enrolling in our X in Looking first kinase programs, for treatment recently pathway, our the trial tumors clinical for we the in

We last programs R&D also advancing number In XX evolved our portfolio are dramatically towards summary, the months. has IND over submission. a of

a have to through promising We our late-stage of in pipeline. the by I've never experienced compounds XXXX, programs, and robust capabilities programs. delivering drive we pipeline integrated to readouts GW complemented the been more mid following With data excited expected development, with goal exceptionally with have further early-stage expertise and team, with rapidly organization our about R&D an patients.. talented, and transaction, the additional diverse innovative the therapies of

Now, call a to pass I off the for Renée update. Renée? will financial

Renée Galá

on slide begin XX. I'll Rob. Thanks,

the We total revenues with to and million, financial $XXX execution same XX% growth quarter of impressive results quarter achieved top in third representing compared the of across Our XXXX. growth business. third strong reflect line quarter bottom

income same bottom XX% the $X.XX the adjusted third our last same the compared for the XXXX. a and drove to XXXX $XXX top compared the growth in million, net year. to XX% EPS a for same quarter, third XQ period EPS would increase the been Our to in XXXX have continued results accounting Adjusted was our XXXX. debt, change period focus adjusted XX% increase line XQ in convertible on Adjusting of for compared both quarter period

on of to end and lower Our our guidance disciplined Based upper on billion ranges $X.X to $XXX year our towards the billion, oncology to total to instances, our product quarter, for and million. net net and the $XXX We sales to OpEx, and billion With to guidance we the is are the updated have use of expense to sales net to $X.X $X.X on noted focus same, midpoint in the million. of to XX. we expense slide guidance revenue guidance $X.X $X.XX billion, we million end. all of expected revenue increasing for range, raising cut outlined full the metrics capital. the product last guidance reducing that quarter we all while guidance results sales our come strategic, and R&D billion to end In from are third to continue SG&A lower $XXX regard $X.XX to three guidance now updating million we $XXX narrowing to neuroscience billion,

and financial We are by excited guidance about primarily program our preclinical was of ongoing the in and programs the pipeline nabiximols R&D and the continued investing focus in discontinuation on reduction discipline. clinical multiple and driven

we Zymeworks, both with of guidance recognized despite fourth of payment a R&D million data payment to related IP pay expect XXXX from included with the We midpoint million to following be million the HSR review anticipate of transaction our $XXX upon to range to in expiration would to billion $X.XXX at in the $XX payments upfront $X.XXX billion. line. continue transaction year-end inclusion This period. of Should by non-GAAP the improvement that we is ANI the Zanidatamab waiting second upfront quarter, decide a raising are $XX our the we the

slide Turning to XX.

non-GAAP the Our leverage at end ratio was times the quarter. net of approximately third X.X

of paying increasing We EBITDA. in have which down through now delevered and the two May we've adjusted the transaction both debt full turns close since XXXX, accomplished GW

is that allocation meaningful provides our ensure business focus with and all to believe the approach Our strategy across priority fit sheet corporate is ideal to strategic value We shareholders achieve exemplifies deliver on highest to for the potential multiple recent are Zymeworks transaction XXXX. flow we development our our Jazz an balance and leveraging flexibility potential strong attention disciplined the Corporate remains cash our Vision this portfolio I'll call important development of has diversify near our a corporate initiatives. our investing and in approval particular BTC. development. our aspects A efforts at managing capital for tumor can types with transaction in and us the we which of term to. patients This initiatives transaction pillar commercial of that and to further to further with long-term initial is growth innovative to for foundational both through following in therapy evaluate few an

where it Zanidatamab Should we US, Jazz's as is Notably, aligned approval our strategic which unmet commercialize we where infrastructure critical Zepzelca concentrated there and the quickly is for BTC with potential with small on significant for first have and a efficiently. built our established standard licensing insights the existing lung the we is relationships and efficient in GEA, also overlap in a universe two focus in and to the integrated and not only can secure we physician where capabilities in First, indications, agreement but care strong call continue unique have of are there's cancer. second-line opportunities cell audience need, existing commercialization. there leverage patient Zepzelca global

as a range robust cancers. approval Second, regulatory And third, opportunity noted, this expiring patent has potential potential a broad exclusivity, for Zanidatamab is asset portfolio years a Rob the several with following durable of significant in and later.

transaction, also continue portfolio, the development deal and coupled on of with weighted bandwidth structure than we point upside is a rather I'll achievement front. offers with to and structure relatively modest flow, that transaction be plenty payments. of to us significant this with active our cash commercial that asset higher investment, a corporate upfront to the regulatory of diversify upfront As believe to we milestones of out look continue our the commercial leaves towards type scope strong and including

with the GW the $XXX nearly ability on to in up noted ended million opportunistically in slide, then the equivalents and delever and respect lever shown with cash quickly and I transact investments. to cash, the order we As to quarter previous transaction, we've

to earnings full As provide disclosure. guidance year XXXX our plan in in prior years, we

to However, comment are items on I'd on two like our Vision that shaping perspective and XXXX. XXXX

upcoming oxybate First, competition.

previously authorized choice noted, Xywav as remain XXXX and expect we've generic and early branded Xyrem of the the competition market, As we that available. to or enters next first will follow oxybate year even the in either potentially others late becomes this year with

We to XXXX Book as patents exclusivity have XXXX listed out for for that orphan drug XXXX. extends that extend well IH, narcolepsy and as to Orange

receive will to expect an by coming the continue of our Xywav, for generics, oxybate the authorized led also royalties to component all revenue we and expect stream Xyrem in We franchise, be meaningful important years.

Second, operating margin improvement.

target shareholders. achieve believe are positioned now in guidance to some Bruce in in R&D call remarks. progress operational XXXX sustainable on the invest XXXX investments, XXXX and our enhanced and to diversification, midpoint, operating XXXX excellence, value I'll business to back outlined both patients well us updated positioning the and Vision growth further XX% we focus and to XXXX. turn and further implies our product at achieve of margin strategic we deliver expanding portfolio, Our Vision final an margin operating the With for and

Bruce Cozadd

finished overall biotech in a XX. an We despite are markets global slide in with and excellent third Thanks, general. and our sector, financial position quarter remarks period strong Renée. on challenging I'll across in momentum business the the conclude prepared our

Xywav as Our lung an launch commercial of for in strong small in efforts cancer. resulted IH, have uptake established choice cell narcolepsy in the Rylaze outstanding both second-line growth and for driven in Zepzelca and Epidiolex treatment

including and R&D our we pipeline continues submit reflects margin, on and drive zanidatamab, In to guidance execution team our several operating XXXX. Vision team's remain achieve add addition summary, to value. late-stage of of updated potential and and XXXX, of also maintaining diligent allocation adjusted INDs area our while capital to and disciplined track our we programs our to improving shareholder business to of key contribute program The over the to objectives. I'd goal to oncology first the pending near-term the three Our for in advance remarks. Operational to mid to our multiple That R&D and focus, anticipated with strengthens the XXXX. through to remains our the call line prepared Vision expect to like open concludes clinical now milestones quarters Q&A. commercial turn operator XXXX across the a excellence

Operator

[Operator Ken Instructions] with Our Cowen. comes first question from Cacciatore

line now open. is Your

Ken Cacciatore

everyone. Hi, performance. great progress, Great

view in that that And is is patients. know on still any past give still field And more that the talk rate? where to talk you're are of you this size going IH? Just still these I number know here as we're clinicians? folks Thanks bolus there equate Can sense had some retention you views think focus on early increasing the you the seeing -- a talk, lastly, -- described Can you're you as experience eventually could narcolepsy of worried maybe us these your to retention you've seeing patient or the achieve then a Bruce, that prescribers. Do an who's -- already Dan, Xywav. adding to repeat in by this seeing the the in you patients? prescribing about the similar being can much. what but was on on Xyrem patients you it, can narcolepsy. so about about described I it's in just initial as Xywav using

Bruce Cozadd

let questions we're then a with opportunity initial I'll and overall the Kim comment market seeing on start the take Yes. on in patient what Ken, maybe experience Xywav. with

size in opportunity that as may, while is we the move you the undiagnosed we and fact, market large very opportunity, do and diagnosed if in On forward narcolepsy believe at the market of look overall patients. size, be time the

we as where patients initial that of Our IH talked seeking segment going actively is are market diagnosis about, and a have focus, care. medical of know after the we've already

So but it's that, larger. is a subset of opportunity yeas, long-term the Kim?

Kim Sablich

those therapy. And to still base the very receptivity saw Phase I'll among level Yes, perform, ultimately, so We're patients. and the as Ken, what emphasize they're the quarter-over-quarter studies. X that have market with for products their IH product you we really in of hearing who that engagement in on we're prescribers seeing high seeing what a line both positive new prescribers utilized experience. safety continuing mentioned, far in the overall grow clinical is and prescriber bring new Sure. wise, And and in we're efficacy this

both experiences patient the product well positive with very the So, formularies. coverage point we've got availability experience in the at time. this for that positive commercial narcolepsy XX% as population on as of in and Again, IH

overall, with seeing a and hearing their population, first-hand and to in observe care prescribing what idiopathic this we're provider gets ability that, the as So Xywav is experience clinical have own health own enthusiasm its can clinical it, start really benefits additional increase to appropriate to practices which within initiate an they and in their effort patients identify about their part see on therapy. we

of track us we're underserved both it and from market, this, well in us makes very continuing the choice that and really as across us signal to pleased of utilized IH as continue not well potential be to maximize have the of to to and narcolepsy to that XXXX. all oxybate really Xywav positive ability those have allows who Xywav those in on this So in grow putting be our confident

Bruce Cozadd

you treat disease And to address our primarily they off-label, indicated broadly I'll important a of number by Ken, had Xywav using is are they to a Xywav available were physicians seeing across the in to unapproved contrast the saying And if symptoms. idiopathic launch EDS. options just them just as before with maybe hypersomnia with drugs reminder, wrap what IH,

we're and seeing that through to clinicians. effectiveness patients And so both come

Ken Cacciatore

Thanks so much.

Operator

question. next Please our standby for

JPMorgan. Our next from with Fye comes question Jessica

Your line is open.

Jessica Fye

influence Does impact your evaluate own And evening, the about business questions. taking Great. within thinking your pipeline? my Does for IRA or on which to or what development Thanks how guys. you indications potential prioritize? priorities targets? Good your it efforts

Bruce Cozadd

implemented IRA development we cost it's our So, across how liked, the are I we're say, investment as here we it portfolio, R& including decisions investment would learn importantly, the guess, impact other address out-of-pocket see evaluate that to and of patients. trying but to how about really companies impact impact industry, continuing decisions, will I time to going across IRA our over corporate our in also parts for particularly more be like to opportunities. may legislation, our of D

are was probably the step I consequences not innovators terms some There we that a other right of a in for those return capital provisions actually recognized the challenging fully consequences in of investments. to terms on think or that direction. in are providing unintended think of

will like looking see into be at will products. that I portfolio believe we're account commercial longer-term our but we take certainly existing decisions. we in concern it period of would for investment We everyone, near-term don't any So think making when much potential impacts. us, we,

Jessica Fye

you. Thank

Operator

comes with question Our Gerberry from America. next Jason Bank of

Your line is open. now

Jason Gerberry

Hey, guys. Thanks for taking my question.

year. think year-over-year just can see be as easier question, it curious drivers for you have helpful some this ask from I'm a revenue two And could a asking that reason growth I XXXX curious think XXXX you believe just growth target the entry, would the at impressive. not quarter you And to is generic like would because standpoint, is if you speak Epidiolex address I out it's threshold. then competitor And directionally on little a I biggest if that just guidance, guys XXXX And to First if bit growth you basis. to an the but a year? the be investor was or think there. given one something

and into pushing were into guys You suburban adults, kind of areas. rural

bigger Thanks. little if growth the specifically drivers So curious just kind could of for of on give were bit you color more Epidiolex? what a us some

Bruce Cozadd

I'll that asking bit growth. little and talk maybe our a broader and trends I Kim and not thank ask you're so take hear you. it about Maybe Dan Renée can to Epidiolex turn for then question, over to revenue the to guidance, I

Renée Galá

Bruce. Jason, Thanks, thanks Yes. question. for the And

to respect alongside our we as the you with first quarter. full So typically full year XXXX, results year would expect, guidance in year new for a that provide

from us So early you can in expect XXXX. that

at Xywav Xywav, you course, results, economics AGs, meaningful as listened third carry to to and of established relative of how However, be of royalties the looked for very deliver billion quarter to AGs broadly, would continue are to We've franchise, choice. revenue we coverage Xyrem the confident expect Xywav we us. path XXXX payer then and more back our therapy But IH. oxybate XXXX Xywav, and branded have we're the which, for say going we and ability to with therapy respect the competition, comments for we us the well the ahead that of I of for $X oxybate have of to across oxybate of about within would excellent believe year. We're be thinking positioned to choice and the XXXX the narcolepsy to in our to or potential both

a now milestone more million another we've we sales third today, with narcolepsy Xywav Xywav. of important patients the heard net than You've also, over in quarter, on for the in have single quarter now brand. And Xyrem, generated XX

success to So and to for us all positions prepare brand progress really and as we the XXXX. well this points of enter meaningful

Bruce Cozadd

Kim?

Kim Sablich

Yes.

start be off really of momentum themes and the US, that talking been have are So by the are for number the giving year optimistic looking the future. us about us a in some talking we I'll for. think US things and about I the past to there about of here seen And we've leading

broadly. early that, The nicely is in a our that continuing given to a grow volume utilize have product is to it and of of to this we HCPs have Epidiolex with overall cycle customers as really or really has such first the important which Dan been number engagement use life as it quarter-over-quarter, mentioned, yet

sensitive, this absolutely So promotion highly promotionally-sensitive operating are that important in in. education and market we're efforts

So one. that's

quantitatively, mentioned utilizing in of research what treatment with more moved and is it patients, their this as and is feeling product HCPs up think more them that we're year broadly. really that more this algorithm. their I that reporting that getting of driver talked Epidiolex, predicted second impressed seeing in XX% Dan we've have of we're showing comfortable of can and do are terms for seeing kind also ago, the the market seeing experience it with versus a about Epidiolex HCPs reality

had So early predicted seeing had on. we that's been and as working exactly

momentum. or on motivating broadly great XX% products together pause. reduction. And that of very impressive. does been give TSC, of its that it HCPs there's either It And is lots them they this first in it really about who again, Clobazam XX% to Clobazam. promotional patients Dravet, time sharing So time utilize terms reduce all really then year, these using are patients LGS the that combination we to seizure that by and it we've on in effect highly them get utilize to most combination It the try talking with point it's the product our effort to us last already tell of been one and from of already focus trying I'll more and has see a they who first data Clobazam. does synergistic the two for have really for for further in their to to in until ability seizures And or by benefit are their when could

that And product but really status. the to sales look I nicely saw at blockbuster wind growth to the is putting just we that we the year-over-year also XX% third achieve So three leading optimism both to as and that's quarter, to and continue those US. in the grow major things things in our leading the going this have

about turn I'll to to it Dan US. the So efforts outside our over talk

Dan Swisher

because few that trends and words, of drivers it's growth I'll say consistent mentioned. a largely Yes, the just Kim with some

reminder, Just XX launched markets we're with XX as in a countries approved.

TSC also still What both geographically we a markets. is HCP sensitive some of and the promotionally same engagement are as a launches, And the so, brand. rolling adding to label, and in of seeing those series it's there's we're

that's country pre-launch very we a secure beneficial. going had successful an France, we've will through is be and be in last launching market in to The major experience reimbursement, to So and did of ATU. pricing and we -- Europe where that sort

that benefiting who've drug commercial that the for already of mode in there's the benefit into a awareness year. of full on moving and next end by into the been So the sort and full year commercial from patients launch

So cornerstone treatment-resistant be we Epidiolex therapy basis also for that of remain a optimistic can and blockbuster product become for this worldwide us. on a epilepsy

Jason Gerberry

guys. Great. Thanks,

Operator

question. Please for stand our next by

Our next comes Amsellem with from Sandler. question David Piper

line Your open. is

David Amsellem

thanks. Hey,

-- as number to talked I'm about, goals, expansion million how about two one. you're is particularly you at how a wondering, think regarding your penetrated in margin Epidiolex, your new $XXX in One what, the particularly it wondering is out getting me. the disclose about And you was in should in of of and that targets, XXXX. to what's for is, in on you're one we XXXX? through two the putting long-term is $XXX if we things So your growth. expense expansion move course, but R&D, target of this into year? in R&D, million How XXXX prescriber think, R&D. guidance And the prescriber pace your control or that's aside you position loud, audience? nabiximols about process that organic Number of Thanks. much near general So XX% I just just just commentary, view are and talked to close the new context growth XX% that, given of on just I'm

Renée Galá

question your margin expansion. I'll of first David, take in terms its Renée.

a our in on of operating operational adjusted have of yes, We've already number being So, excellence. of focused And, today guidance for we're highly the we a terms of XXXX my position ambition margin the XXXX. through and comments at been midpoint that certainly, accomplished in XX%, areas. being we've year out where XX% set a full at for

pipeline. R&D accommodate well investments additional R&D largely SG&A accomplish, course, to But forward able decision overall development, to program be look to business additional to continued ultimately, said we're looking better able what as the Of we due we're at to leverage we accommodate in was nabiximols be discipline. our trying in favorable, to as as to

leverage generate have now our pipeline. And that commitment We our answer But in we're out brands gives question. so, the our opportunity to the the expand second already, pipeline, are R&D business, our enhanced future which, of grows more our as invest to to And XXXX, commercial that continuing shareholders. could with efficiently, GW, pipeline being we be the and to, effectively expenses. and have by Dan active in an can will still top and then now the the or development, so for capabilities it transaction G&A that over I'll between it position we would scale us over value in continue corporate invest area line footprint time, capabilities, capacity expect launching, we certainly then of course, for across to result additional have to your that's patients to in turn we and in and coming R&D a to continue that

Dan Swisher

Yes. Thanks, Renée.

in the of the we're had smaller and specific penetration Dravet indication. on opportunity. the that but past we see rates, not we because yes, TSC, said more So Epidiolex, LGS little more giving a penetrated is

the many drug see just of that seizure also number populations works these therapy. don't broadly refractory types that and make there's up FDA-approved different in a that We have

focus a all it's And then of terms beneficially use market and a we've for physician So question going experience There's seen access. of retention, as very in lot of that's and us strong well. retention. and

a within they So this polypharmacy drug, the a very when setting. find patients beneficial be start to

they doses and that leads push see gain to generally better that also also that, We as the physicians experience efficacy. up

I we And so feel continuing we're the titrate under-dosed. to think in and markets, some of up,

with there's then the address conditions there's investing we're we've looking such and in markets. also starting and markets at we to a Asia. Japan longer pediatrics and we're types patient new also got adult settings indication in population. still going But the countries think those even all then, transition the an And to haven't data And the lifelong like EMAS of still significant I up been good to seizure they an addressing become these in with for opportunities of a in. but term, new area as adults geographic going for So generation additional as some and we've way young adults done job broad that's opportunity be a most age young And pediatric growth.

David Amsellem

Good. Thank you.

Operator

Please standby for question. our next

Marc Our next question SVB. from comes with Goodman

Your now line is open.

Marc Goodman

could Last more, it strong. Epidiolex maybe us then kind a help just quarter was bit weak little on you it the extremely quarter, but quarter keep fourth was to a sorry I'm and third Yes. year, in of here.

that. a was taking from the little And stuff like bit inventory quarter any there away and so one question other, of the movements

you pretty can just just to it the expect just or in well can to was Epidiolex before European us in understood. it. about -- then the excitement? there was there something that? getting usage, you you so was Do them any this and was buy obviously, Is confirm curious, that CBD quarter, it same quarter, of States? of study. It United I year-on-year, type this is in approved very double-digit lot of actually you a same growth help do, understand Thanks. talked United Was the was help you Japan the And was up if there and just we're all can Like, added that lastly, the and in like in there the understand in thing trying of out Bodega, over there all and was just tease was US the over Japan? any type ramp just there Europe, there growth a place. the like Maybe on And regions inventory real over States change? big

Bruce Cozadd

going the in it's out part It's new are as the US Yes. US in to Bruce. as inventory. Yes, due Epidiolex continue take of saw you indications on Japan? growth make maybe described answer. a question of comments the seeing no, a Dan, and Japan. we short take you countries your first Mark, we couple want is growth to Dan Europe, be in new roll to to in in changes and not solid have this and I'll real. it's Dan The then in is

Dan Swisher

Yes.

for now the interested non-regulated. have developing cannabis Epidiolex. we're thought no the But market whether is study regulatory was and Cannabis which markets, launched in with very unlike so side, coming of excited the to official or really out other who use very leaders and prevents closely the worked data vector, that there On we're that Act, it's our regulated of needed allowed super agency and Japan Control

done confident in also geographies that feeling to government Control change meanwhile, exceptions do Cannabis working GW we're from officials we're sort for change be to a safety experience the that have And and enroll regulated of clinical evaluation. successfully to as other the through and practice. had and Japan parallel with And we'll efficacy get of of allow the law then medicines within so gone in so study. And Act able for

So we with where that's are Japan.

Marc Goodman

Thanks.

Operator

question with next Our Ami from Instructions] Fadia [Operator Needham. comes

line is open. now Your

Ami Fadia

Thanks. need the to you can then Thanks Vision for where meaningful think question. a There's about you you is consensus and your -- be between confident My more might gap talk for question to of that the outlook XXXX. Thanks. the new to able in be you billion business? on future performance get to And or the rely $X to successes do extent to number? order business development pipeline in what

Bruce Cozadd

placeholder for from make thanks more strong Yes. that can out would a question. talked about we and/or for our doing we to existing Hi, a first our of XXXX, comments including corp productivity a when communicated also with commercial and portfolio, commitment corp pipeline I about even revenues say dev. but Ami, we're dev maybe having Renee few And the that. thinking how about Vision

Renée Galá

revenues I'd continue diversify look Well, to happy corporate on date to Clearly, as our for our we and had to. and impact grow expect to be it huge us. Ami, also Sure. pillar important be pipeline. forward, Yes, expand ability an to strategic we our a development certainly

of we've as corporate as the to the with from end it had $XXX five mentioned, part on we you contribute development, XXXX novel the as the both future Bruce part deal decade. as deliver by of of growth transacted potential, just to So look at the million identified but therapies placeholder the Zanidatamab, also to has Vision in

flow, being therapy. us think sort have to potential This we we're to contribute we meaningful the a looking to that that opportunity able that things I'd two at put the has of for commercial. in have different pipeline, strategic late that zani for corporate category look best-in-class but framework excited close early to case very molecules can and zanidatamab grow to of terms assets that we is at then pillars. where be that And patients, As to we're also continue in also potential development, of impact to in our delevered given financial continue be the for commercialize insights, right we'll the transaction the our at unique a of with And speed the where now Zepzelca. and have overlap apply ability given we've transactions efficiently then, can to this which we nature. just note, position to just the look And at valuations our I'll of development our as opportunities, see leverage and group quite in course, they corporate we operating corporate to where forward, ability given the confident of health of are We, cash to a busy. feel lot still today, have that's look developments. continue a we

our we're business to the excited So to to have We're continue we to top forward already about a really with drive part opportunity the we continue grow pipeline with lean as have we that today. the excited augment in-house about business. and what of line what opportunities have into to the

Ami Fadia

Thank you.

Operator

question. next our for by stand Please

comes from Our next Verma with question Ash UBS.

Your line is open.

Ash Verma

question. Thanks taking Hi. for my

one. Just

patent IV on So certification? Paragraph you have the Thanks. confirm Can I there forward think visibility on XX. Epidiolex, if NCE whether plus any passed you timeline were September

Bruce Cozadd

clear time. made we've over that than filings other occur. could fully be We add the may to in our filings Nothing filings expect there that's earliest

Of us at FDA to the this course, report into those and nothing to come go first point. but later,

Ash Verma

Okay.

Operator

Please question. stand next for by our

Sachs. comes from Madhu Kumar question with Our next Goldman

line now Your open. is

Madhu Kumar

for Thanks taking question. Great. our

they further a IH of to with about how like, hypersomnia, should that that? you be look more the As up get could how and growth trajectory a ramp further There it. experience now. like happen? on think curious with expansion Do and you how are get comfortable like kind idiopathic they kind mentioned, physicians -- about, to tick We up Xywav of think as of, kind Xywav, kind in we think you there's at of in

Bruce Cozadd

to for bit future Kim, Yes. you a growth little do want with talk IH? about opportunity

Kim Sablich

Sure.

marketplace, care. health past opportunity actively talked there about out for and already growth. We've being there they're of in lots patients diagnosed IH out in with the So XX,XXX the are seeking who actually

not So diagnosis. it's sales a

symptoms into to Xywav. a try they're weight-promoting really that that And patient of them patients enabling more that make want patients sure ensuring focusing So want go and making that patients address, given secondarily, now ensure IH much HCPs population about Xywav diagnosis. ready educating Despite who have they're really big to sure been we on breadth experienced, the is we're we sleepiness that that on to full and broadly we've experiencing nice, we're we're helping to taking around usage used identify this, focused to daytime after. healthy around right full the really stimulants What that that excessive HCPs are agents off-label maybe to of range they're be of symptoms consideration then are that of a help mostly symptoms. thinking part of about for is and And breadth treat. can to thinking the again, they're got

So narcolepsy, that overall, we've I excited excitement strong is the expect gradually. a grow and it said, build we for like and hypersomnia did And idiopathic just market, to we long in as will take with feedback it a time we're some market. new time but think but now,

working hypersomnia, reasons of is there successful to more in plan lots overall, now. the Jazz market ultimately a in we decade to optimistic, idiopathic but to some Xywav And it for been will time. with be be or take appreciate, So narcolepsy also but

Bruce Cozadd

that the Kim of reduction mentioned can that Xywav of see the narcolepsy for trying what product and to in grant messaging the the continue remember, -- our things narcolepsy. importance two events. but is FDA based community, to force in the of add that And and maybe that the sales in we really lowered our adoption new cardiovascular drive because a that, market exclusivity here, I'll led including also Kim do sodium about orphan on mean IH, sodium safer to

as to that we IH. messaging narcolepsy continue to do important grow in So,

Madhu Kumar

corporate should you of development, it's outright you Okay. individual guys acquisitions about And a like we pulling will of then Zymeworks GW? or development, deleveraging. corporate think you how rate of of forward? on impressive assets kind that the think about may guess partnering like out of it we where like guys kind have in terms kind the be How future I as really

Renée Galá

about... talk to happy I'm Yes,

Bruce Cozadd

talk you of breadth Yes, Renée, why the don't Great. about approaches? Yes.

Renée Galá

Yes.

Sorry Yes. that. about

two as which corporate we meaningful of fact – as -- think did to all we is in So we're full down of across very that about. combined greater the of create research opportunity We over our first early that a have different the capabilities, million in a decide in it we opportunistic should we looking million, to that we means us on of XX%, data, debt forward. about paid including and something has aspects the deal pivotal QX generated at as the said, and north really of of to $XXX well at our strength our close capabilities now capacity continue a then we I've and can $X we cash turns EBITDA, to flow, we over we think of down to do our Zani lot strength excited The really and do opens The we than when our expanded value with in a being want for important adjusted cash be up flow, levels. Sumitomo, and position two we to business have operating opportunity, which look transaction with look $XXX debt. think over time. we that pipeline billion the stage potential greater the and And pipeline, optionality I scale. larger both by Werewolf that today, quite continue through of assets closing months. that more But de-levered ones paying transactions like a as to step us will did since our to back lot EBITDA the be cash deal, XX% development ability the With nine us places transact and increased at we for able

and in do And and We our focused between at also within molecules tend that, other then areas shareholders. primarily onc. on really are think and for to look biggest focus the meaning we we patients We for opportunistically. have we large smaller agnostic, could where be neuro impact technology

Bruce Cozadd

Operator?

Operator

from Balaji with Our Prasad next Barclays. question comes

Unidentified Analyst

is for [ph] Joe Thanks for Good question. afternoon. This our taking Balaji.

would -- breast quick We that know deal. likely based the from bigger the the I'm readout wondering, GEA highlight Just like a for through other optionality of anything that GEA on just in will here? market in cancer the that the the terms be a portion interesting? one would factor much. risk of pivotal BTC small so breast timing to terms you to Zani continued BTC be BTC on of and Jazz rest revenue the is Is there relatively a pivotal you the the thinking cancer. and of Thank and find is of indications indications from the like data like for

Bruce Cozadd

talk you about think what in we're broader to ask thinking I'll the we'll about Maybe near and Yes. we Rob, set. the opportunity how learn term

Rob Iannone

with I've say across HERX to. Sure, is drug in I would express and impressed HERX the any really been that answered directly before even this cases broad Bruce. of progressed after I What activity therapy. have tumors question the types Happy patients where

would promise, submission we And FDA, around is that's marketplace such NCCN readout we'll us its even based Remember, a be BTC review specific It rapid get speaks studies indication. the a data near-term BTC would that before guidelines relatively and with we're say BTC, et chance more colorectal in we sense whether doing it would gastric a as well. on a by cancer then if even at would that small as the preparation I just a so could next and the supplemental. gastric see get in the it mean to published in and mean I and the we'll indication, And gives file some additional us that give in do approval to have important to approval beyond. beyond the And going of cetera. both potentially breast opportunity cancer, think BTC. to What

the it's So of I But gastric trial. to I think don't to going expect ongoing through that becomes regard. a factor in that a that read kind direct have

Unidentified Analyst

Thank Got so you it. much. This is very helpful.

Operator

comes question Gary Markets. Capital BMO with next Our Nachman from

now is open. Your line

Gary Nachman

Good Thanks. afternoon.

Or strong reimbursement for the in uncertainty can Just to already payers, market the back for forms on certain confirm depending year? generic is Xywav, for still is Xyrem. there to you locked next that be there how you that going locked some have

And in the much generally, how increase as as did So narcolepsy continue in how negotiations awareness definitely Thanks. the IH take well patients IH? number of – you treated then helped those launch narcolepsy, with not just place? is overall of to

Bruce Cozadd

Yes. want to do that? you Kim, take

Kim Sablich

Sure. Yes

coverage, can that scenario Xywav We So conversations heading at our will year. their hypersomnia. as the to commercial have most be think that payers mean, what comparable put just about say point place. believe us you bodes And we've formularies asked in I AG well got this and terms I narcolepsy in into in I generic payers the is strong the coverage of contract for time put position based on in idiopathic XX% is for authorized the that we very well next in XXXX we Xywav. on – of with think to as that that going the likely really a on both

for narcolepsy, much force are same with the those overlap narcolepsy, I'll is look, so of with discussions. of just Bruce we're times that the can just that but not getting IH into already the on now with a we that of that awareness IH customers same disease, helping calling the out terms there largely what many overlap wherever say to sales targets we're we due mentioned, it's XX% In around the

in itself. of the essentially, promotion doubled we've So many the around amount cases, brand

for that leads indications. in So just I directions both that, both do believe momentum overall to

Operator

Please standby for our next question.

Our next comes from with question Annabel Samimy Stifel.

Your lie open. is now

Annabel Samimy

going a point gradual it had growth patients, ask to trajectory AYA think How When from growth? a from curious the Is about that higher the about plateau? level, Or of than here Is nice tapped X you a about growth Erwinaze. it new we wanted to this harder a is see into here, is plateauing to Just dynamic we just seem a uptake. LDL I'm you the really think have should given little How it be peak should if this pediatric to here? patients? about to it Rylaze. bit obviously, market? obviously, think forward? geographies? Is get you

Bruce Cozadd

US? want with to Kim, you the start

Kim Sablich

take exceeded that have needs to Erwinaze of Erwinaze fully of met happy believe had be that never peak this before and the pleased U.S. sales a market Rylaze signal because is incredibly sales to one unmet are the I'd strong really we that been have Yes, we that prior issues. started supply

as brand point of the enjoy reliable who also position prescribers. customers and see asparaginase. in in therapy We're availability young number continuing available said, have the high increasing to of in the they have you encouraged patients Rylaze derived oncology US, are to earlier in right We switching hypersensitivity is hear of coli-derived of But the we're to on E. confidence when almost that and now initial see of reaction protocols. there has hypersensitivity point, supply non-E. At only I'll practice shortage from as treatment the the high-quality a asparaginase things. they to based they universally than and awareness We've adopted, been use adolescents that supply to that adults. we customers coli And among product. returning the observed. created clinical were So the to previously kind a and the reaction during robust Rylaze pediatric that of Rylaze this to now,

it's strong really many under young note majority important in treated patients pediatric. actually and adult are the out there the Now, are And pediatric patients that the protocol. adolescent centers of to pediatric

good a driver that's So the of growth.

on year in prescribing with focused expand the the in asparaginase who, to existing adolescent was launch setting. our establishing further young next prescribers aim Our if market. we XXXX, driving and seeing efforts in increase to last predominantly pediatric were again, can -- adult we our And the in year the Rylaze population

for US. to there's opportunity just that's And inside ex-US growth again, certainly, Dan talk lots of about. So the

Dan Swisher

Thanks, Kim. Yes.

EMA, US, and potential hoping to a of et there. how outside mentioned, XXXX, that as on in questions, long a approval with market the filed cetera. we different the depending we're and the over for On we've answer It's takes

ensure solution. these then till coverage fully full Monday, on setting. in pricing we've terms experience with the patients. the course, Wednesday, European particularly is being the said, dose in market advantages Friday for ready concentration, particulates recombinant, no US is the bigger having had And a within dose the and the there's on other Of the Friday Erwinaze really in optimized, the also to lower of That and

on this to path opportunity another So we're be forward one. get it. we yet medicine are actively who Europe, is, -- not those option important the where regulators giving And Erwinaze is from we patients some there see, to do we'll Outside look the of market. countries considering treatment there to the physicians. there Japan do an expedited with what and is to to working benefit could is

Operator

by stand Please our for next question.

comes RBC question from Capital. next Renza with Our Gregory

Your line is open.

Gregory Renza

some to that, years for the forward? and back I'm potential specific updated Hey, taking just the wanted hear much. like Jazz, team's question. as on ask looking strategy and to and one you trajectories evening, here? as ago color deals from maybe related can and and that a team. now then Thank potentially far how thanks on Vyxeos And give the zani on view under as Bruce quarter just you on at color performance and on zani as Perhaps super to Bruce, and good Vyxeos. Congrats going blueprint. how Celator with few curious, Vyxeos the a very you, helpful elaborating reflect just you're to juxtaposes us I BD from my it's Renée

Bruce Cozadd

commercialization. brought the as learn And strategy Celator near-term important your question. in remains deals interesting that development dev CombiPlex always for going to other forward. future. Vyxeos we in under from allow we the US corp remind you source and future on may for study products that deal, in as In I'll your with market as use abroad launch thanks inside areas our the Greg, outside us platform, And other interesting to now the broaden think a of to the continue as we Yes, a and past which consider in and the just see AML Vyxeos you well

of Renee, is maybe, forward. approaches right corp moving you little dev in So now? then bit talk how can how about jump the being And Rob, Vyxeos studied Rob? prompt maybe to different about with a think we

Rob Iannone

Bruce, Sure, thanks.

number as combinations in well groups ways would a could and of studies patients, such through with venetoclax. trials be we're the just the highly in be just as of also studied the would things. Those conducting. ISD's of being collaborations broadly, in couple relevant, group group would a that it's that seek more extend some trials front as AMLSG, cancer I major different indication is combinations cooperative not centers So that One with broader And highlight ongoing patients cooperative line. high-risk ongoing. to to like which are with but And a

Renée Galá

development business Yes. And it out of just I'll in terms going cap then forward.

the upfront we and term we're terms these and drive looking risk also just balance we points, to not also driven transaction, were at forward, value look we outlays value are team leverage with But with at terms the structured that balance the and as look future transactions in that commercial looking able look inflection right upfront at with the continue monetary only that it at as if And that studies the transaction, to financial regulatory in So we've primarily I the how that to to the that. strike points. with we bringing our inflection meeting to skills financials other to structured be also enter near and we to deal and were to pleased balance that we in and in of while advance by Zanidatamab we continuing Certainly, partners how into in between the that strategic this creative leverage continuing be superpowers our table value their objectives can they're ensure are of Zymeworks able for particular, are the inflection ways strategy. our -- and points. to milestones to strike excited looking

financial to well the and win-win optionality patients our we ways both continue structure forward, from transactions creative with So well to have our partners. having a as as that going perspective shareholders business as outcomes have to a we'll broader at both for now, and look as Jazz

Operator

am for no turn Bruce I At conference questions. time, this would the to now I remarks. like closing showing to back further Cozadd

Bruce Cozadd

Michelle. Thanks,

We therapeutic I'd look options collaboration a patients to their by and continued to shareholders us, and thank to Vision like colleagues good Have everyone. to partners XXXX want Jazz strong support. So and commitment to our evening, to thanks a close focused XXXX. delivering for their and for And our everyone. remain on for today's achieving recognizing finish call forward joining just new

Operator

Thank This you concludes call. participating. conference for today's

now You disconnect. may

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.